Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database

Background/Aim: The systemic administration of anticancer drugs may cause ocular adverse reactions (OARs). However, such adverse events are generally rare and occur with an unknown frequency. This study aimed to investigate the tendency of occurrence of OARs induced by systemic anticancer drugs using a large spontaneous pharmacovigilance database in Japan. Patients and Methods: The safety signals for eight OARs (periorbital and eyelid, conjunctival, corneal, scleral, lacrimal, lens, retinal, and optic nerve disorders) and their associations with anticancer drugs were evaluated by analyzing reporting odds ratios (RORs) and information components (ICs) based on data from the Japanese Adverse Drug Event Report (JADER). Results: Safety signals associated with anticancer drugs were detected for periorbital and eyelid disorders (imatinib), conjunctival disorders (imatinib and lapatinib), corneal disorders (S-1, erlotinib, capecitabine, cetuximab, gefitinib, vandetanib, trastuzumab emtansine, lapatinib), lacrimal disorders (S-1, pembrolizumab), lens disorders (lenalidomide, pomalidomide, elotuzumab, tamoxifen, bexarotene, venetoclax), retinal disorders (encorafenib, binimetinib, tamoxifen, nab-paclitaxel, trametinib, dabrafenib), and optic nerve disorders (tamoxifen and blinatumomab). Some anticancer drugs showed differences in safety signals based on sex and age. Conclusion: Safety signals indicative of the risk of occurrence of OARs were observed for several anticancer drugs, and several hitherto unreported ocular adverse events requiring caution were also detected. Our results will help predict the occurrence of OARs by oncologists, ophthalmologists, pharmacists, and other healthcare professionals.

[1]  P. Kuang,et al.  Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis , 2022, Clinical and Experimental Medicine.

[2]  Y. Yano,et al.  The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study , 2022, Therapeutic Innovation & Regulatory Science.

[3]  H. Teramachi,et al.  Angioedema Caused by Drugs That Prevent the Degradation of Vasoactive Peptides: A Pharmacovigilance Database Study , 2021, Journal of clinical medicine.

[4]  J. Peterson,et al.  Epidermal Growth Factor Receptor Expression in the Corneal Epithelium , 2021, Cells.

[5]  Meifen Zhang,et al.  Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study , 2021, Frontiers in Oncology.

[6]  L. Mouthon,et al.  Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization Pharmacovigilance Database. , 2021, Ophthalmology.

[7]  Prashant D. Tailor,et al.  Ocular Toxicity of Targeted Anticancer Agents , 2021, Drugs.

[8]  S. Grosicki,et al.  Elotuzumab in the treatment of relapsed and refractory multiple myeloma. , 2021, Future oncology.

[9]  R. Berger,et al.  Ocular side effects of novel anti-cancer biological therapies , 2021, Scientific Reports.

[10]  A. T. Freeman,et al.  Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab , 2020, Translational lung cancer research.

[11]  Helen X. Chen,et al.  Ocular adverse events in PD-1 and PD-L1 inhibitors , 2020, Journal for ImmunoTherapy of Cancer.

[12]  Kazuo Takahashi,et al.  Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency , 2021, In Vivo.

[13]  K. Ohyama,et al.  Association between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database. , 2021, Drug discoveries & therapeutics.

[14]  L. Dalvin,et al.  Ophthalmic adverse effects of taxanes: The Mayo Clinic experience , 2020, European journal of ophthalmology.

[15]  T. Meirson,et al.  Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis , 2020, Ocular immunology and inflammation.

[16]  I. Oztop,et al.  A cross-sectional optical coherence tomography study in patients on taxane-based therapy and a case report with the literature review , 2020, Cutaneous and ocular toxicology.

[17]  Abnormal , 2020, Definitions.

[18]  D. Nam,et al.  Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors , 2019, BMC Ophthalmology.

[19]  Suhwan Lee,et al.  Prevalence and Risk Factors of Tamoxifen Retinopathy. , 2019, Ophthalmology.

[20]  Y. Uesawa,et al.  Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database. , 2019, Biological & pharmaceutical bulletin.

[21]  H. Denys,et al.  Corneal features in trastuzumab emtansine treatment: not a rare occurrence , 2019, Breast Cancer Research and Treatment.

[22]  Ramsis Benjamin,et al.  Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors , 2018, Annals of Hematology.

[23]  H. Qiu,et al.  Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1 , 2017, The Pharmacogenomics Journal.

[24]  S. Stilgenbauer,et al.  Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia , 2017, OncoTargets and therapy.

[25]  H. Hayashi,et al.  Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database. , 2017, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[26]  S. Imoto,et al.  Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody–Drug Conjugate for Breast Cancer , 2016, Cornea.

[27]  P. Bedard,et al.  Ocular toxicities of MEK inhibitors and other targeted therapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  C. Sotozono,et al.  Predictive factors for ocular complications caused by anticancer drug S-1 , 2016, Japanese Journal of Ophthalmology.

[29]  Y. Kinosada,et al.  Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events , 2015, Journal of Pharmaceutical Health Care and Sciences.

[30]  Kunihiko Takahashi,et al.  Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases , 2015, Drug design, development and therapy.

[31]  Kyeong Hwan Kim,et al.  Corneal Limbal Stem Cell Deficiency Associated with the Anticancer Drug S-1 , 2015, Optometry and vision science : official publication of the American Academy of Optometry.

[32]  P. Cumberland,et al.  Active surveillance of visual impairment due to adverse drug reactions: findings from a national study in the United Kingdom , 2014, Pharmacology research & perspectives.

[33]  J. Kempen,et al.  Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. , 2014, American journal of ophthalmology.

[34]  E. Midena,et al.  Cytostatic and Cytotoxic Effects of 5-Fluorouracil on Human Corneal Epithelial Cells and Keratocytes , 2013, Cornea.

[35]  K. Sugiyama,et al.  Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug , 2012, Japanese Journal of Ophthalmology.

[36]  K. Shimizu,et al.  A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1 , 2011, Japanese Journal of Ophthalmology.

[37]  D. Sarraf,et al.  Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. , 2007, American journal of ophthalmology.

[38]  A. Omoti,et al.  Ocular toxicity of systemic anticancer chemotherapy , 2006, Pharmacy practice.

[39]  A. Fukushima,et al.  A case of tamoxifen keratopathy. , 2006, Archives of ophthalmology.

[40]  J. Ajani,et al.  Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. , 2005, American journal of ophthalmology.

[41]  J. Elston,et al.  Tamoxifen optic neuropathy. , 2004, Clinical & experimental ophthalmology.

[42]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[43]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[44]  W. D. Henner,et al.  Severe ocular irritation and corneal deposits associated with capecitabine use. , 2000, The New England journal of medicine.

[45]  A. Sasco,et al.  Tamoxifen and ocular toxicity. , 1997, Cancer detection and prevention.

[46]  T. Vinding,et al.  RETINOPATHY CAUSED BY TREATMENT WITH TAMOXIFEN IN LOW DOSAGE , 1983, Acta ophthalmologica.